Ben L. Da
YOU?
Author Swipe
View article: Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐<scp>IFNα</scp>‐2a as Treatment for Chronic Hepatitis Delta
Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐<span>IFNα</span>‐2a as Treatment for Chronic Hepatitis Delta Open
Background and Aim Bulevirtide (BLV) leads to beneficial virologic and biochemical responses when given alone to treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic viral hepatitis. We evaluated 48 wee…
View article: 3D modeling to predict vascular involvement in resectable pancreatic adenocarcinoma
3D modeling to predict vascular involvement in resectable pancreatic adenocarcinoma Open
Our pilot study demonstrates that 3D segmentation can provide additional information for choosing the best treatment strategy and surgical plain in patients with BR-PDAC. Especially for upcoming mini-invasive techniques like laparoscopic a…
View article: Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48 Open
Background and Aims The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients with chronic hepatitis delta (CHD). Me…
View article: Advantages of Using Blunt Cannulas for Lipolytic Injections in the Treatment of Submental Fat: A Prospective Cohort Study
Advantages of Using Blunt Cannulas for Lipolytic Injections in the Treatment of Submental Fat: A Prospective Cohort Study Open
Manufacturers recommend using sharp needle to inject lipolytic injections for Submental fat. To study the advantages of using blunt cannulas for lipolytic injections in the treatment of submental fat. We used sharp needle on one side of th…
View article: Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D Open
The combination of 10-mg bulevirtide plus peginterferon alfa-2a was superior to bulevirtide monotherapy with regard to an undetectable HDV RNA level at 24 weeks after the end of treatment. (Funded by Gilead Sciences; MYR 204 ClinicalTrials…
View article: P132 Continued treatment of early nonresponder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis delta (CHD) through week 96 leads to improvement in virologic and biochemical responses
P132 Continued treatment of early nonresponder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis delta (CHD) through week 96 leads to improvement in virologic and biochemical responses Open
Bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, is conditionally approved in Europe for treatment of CHD, yet optimal treatment duration and the potential benefit of continued treatment for early virologic nonresponde…
View article: A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D Open
After 48 weeks of bulevirtide treatment, HDV RNA and ALT levels were reduced in patients with chronic hepatitis D. (Funded by Gilead Sciences; MYR 301 ClinicalTrials.gov number, NCT03852719.).
View article: Diagnostic value of whole-mount crypt analysis of ileal biopsy specimens for the patients with familial small intestinal neuroendocrine tumors
Diagnostic value of whole-mount crypt analysis of ileal biopsy specimens for the patients with familial small intestinal neuroendocrine tumors Open
Background and Aims: Early-stage small intestinal neuroendocrine tumors (SI-NETs) are generally asymptomatic and difficult to diagnose. As a result, patients often present with late-stage incurable disease. SI-NETs originate from enterochr…
View article: Pathogenesis to management of hepatocellular carcinoma
Pathogenesis to management of hepatocellular carcinoma Open
Hepatocellular carcinoma (HCC) is the most common primary liver cancer whose incidence continues to rise in many parts of the world due to a concomitant rise in many associated risk factors, such as alcohol use and obesity. Although early-…
View article: Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts
Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts Open
Da BL, Satiya J, Heda RP, et al. Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S5-S14.
View article: Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era
Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era Open
Background. Without available curative therapies for delta hepatitis (hepatitis delta virus [HDV]), hepatic decompensation and hepatocellular carcinoma (HCC) among HDV patients often necessitates liver transplantation (LT). The objective o…
View article: Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis
Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis Open
In order to determine the relationship between socioeconomic deprivation and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), we retrospectively reviewed the electronic medical records of 1,430 patients in a la…
View article: Impact of COVID‐19 Pandemic on Liver Transplantation and Alcohol‐Associated Liver Disease in the USA
Impact of COVID‐19 Pandemic on Liver Transplantation and Alcohol‐Associated Liver Disease in the USA Open
Background and Aims The surge in unhealthy alcohol use during the COVID‐19 pandemic may have detrimental effects on the rising burden of alcohol‐associated liver disease (ALD) on liver transplantation (LT) in the USA. We evaluated the effe…
View article: Durable virological response and functional cure of chronic hepatitis D after long‐term peginterferon therapy
Durable virological response and functional cure of chronic hepatitis D after long‐term peginterferon therapy Open
Summary Background Hepatitis delta virus (HDV) infection is the most aggressive form of chronic viral hepatitis. Response rates to therapy with 1‐ to 2‐year courses of pegylated interferon alpha (peginterferon) treatment are suboptimal. Ai…
View article: Cholestatic liver injury in COVID‐19 is a rare and distinct entity and is associated with increased mortality
Cholestatic liver injury in COVID‐19 is a rare and distinct entity and is associated with increased mortality Open
Dear Editor, Current evidence indicates that the development of acute hepatocellular liver injury during coronavirus disease 2019 (COVID-19) is associated with more severe COVID-19 disease [1]. Since SARS-CoV2 is able to enter the liver vi…
View article: Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation
Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation Open
In this cross-sectional study, HCV-positive donors were younger and healthier than utilized HCV-negative donors. Significant differences exist in the utilization of HCV-positive donors across the 11 Organ Procurement and Transplantation Ne…
View article: Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin-6
Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin-6 Open
Liver injury is commonly seen in coronavirus disease 2019 (COVID-19); however, the mechanism behind liver injury, particularly in patients with severe and critical COVID-19, remains unclear, and the clinical course is poorly described. We …
View article: Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?
Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened? Open
INTRODUCTION: The American Association for the Study of Liver Diseases recommends hepatitis D virus (HDV) screening in certain high-risk groups; however, the effectiveness is unknown. METHODS: A study of North American patients with hepati…
View article: Kinetic patterns of liver enzyme elevation with COVID-19 in the USA
Kinetic patterns of liver enzyme elevation with COVID-19 in the USA Open
COVID-19 is a global pandemic that started in Wuhan, China. COVID-19 related liver enzyme elevations have been described however the clinical presentation, enzyme kinetics, and associated laboratory abnormalities of these patients have not…
View article: Vibration‐controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection
Vibration‐controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection Open
Noninvasive detection of cirrhosis via vibration‐controlled transient elastography (VCTE) has revolutionized the management of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. However, VCTE has not been studied in chr…
View article: Portal Pressure in Noncirrhotic Portal Hypertension: To Measure or Not to Measure
Portal Pressure in Noncirrhotic Portal Hypertension: To Measure or Not to Measure Open
Da, Ben L.; Surana, Pallavi; Kapuria, Devika; Vittal, Anusha; Levy, Elliot; Kleiner, David E.; Koh, Christopher; Heller, Theo Author Information
View article: Twitter As a Noninvasive Bio‐Marker for Trends in Liver Disease
Twitter As a Noninvasive Bio‐Marker for Trends in Liver Disease Open
With the success of hepatitis C virus (HCV) direct‐acting antiviral therapies, there has been a shift in research focus to the other major chronic liver diseases (CLDs). The use of social media, specifically Twitter, has become a popular p…
View article: Stimulating More Than Just the Granulocytes: Drug-Induced Liver Injury From Filgrastim
Stimulating More Than Just the Granulocytes: Drug-Induced Liver Injury From Filgrastim Open
Granulocyte-colony-stimulating factors such as filgrastim are currently used for multiple indications, one of which is administration to healthy donors for allogeneic stem cell collection. So far, filgrastim has not been described as a cau…
View article: Hepatitis D infection: from initial discovery to current investigational therapies
Hepatitis D infection: from initial discovery to current investigational therapies Open
Hepatitis D is the most severe form of viral hepatitis associated with a more rapid progression to cirrhosis and an increased risk of hepatocellular carcinoma and mortality compared with hepatitis B mono-infection. Although once thought of…